Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leukemia: early-phase trial registry
51 of 274 indexed Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #35 of 28,707 conditions by registered trial count.
274 US clinical trials · 51 currently recruiting · #35 of 28,707 conditions by registered trial count
Leukemia: 274 US clinical trials tracked, 51 recruiting.
Leukemia is the subject of 274 registered US clinical trials on ClinicalTrials.gov, 51 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 193 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 37 of these trials.
Enrollment posture brief
Registry condition leukemia
OPEN 51 | RECR 19% | LATE 19 | EARLY 193 | RANK #35 | SPON 37
Volume-matched condition peers
Nearest open-share peer: Rheumatoid Arthritis (19% recruiting · 199 trials)
Leukemia lists 51 open slots (19% of 274 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leukemia is recruiting below its size-band peers.
51 of 274 indexed trials (18.6%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 37 of 274 trials (13.5%). 84 distinct sponsors appear on at least one study for this condition label.
-
Most Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 234 trials that report a genuine target (sentinel values excluded). 170 of those (72.6%) plan for fewer than 100 participants.
-
Leukemia research is mostly interventional.
243 interventional and 31 observational studies make up this index (88.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
274 total, page 4 of 6
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Children's Oncology Group
NCT01164163
Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
NCT00002844
Natural History Study of Patients With Chronic Myelogenous Leukemia
Dana-Farber Cancer Institute
NCT00429910
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
NCT00578942
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
Duke University
NCT01904175
Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy
Pack Health
NCT05064787
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
NCT00003398
Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Roswell Park Cancer Institute
NCT00096044
Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
NCT00267059
Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome
St. Jude Children's Research Hospital
NCT02859389
BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate
Jonsson Comprehensive Cancer Center
NCT00064233
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Masonic Cancer Center, University of Minnesota
NCT00602693
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission
University of California, San Francisco
NCT00305708
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University
NCT00606437
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
NCT00048412
Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation
Case Comprehensive Cancer Center
NCT03342196
A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia
Wake Forest University Health Sciences
NCT01656031
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT00534118
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
NCT00955916
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Memorial Sloan Kettering Cancer Center
NCT00423514
Exercise Program for Adolescents and Young Adults With Cancer
M.D. Anderson Cancer Center
NCT00502749
BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
MedImmune
NCT00074048
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT01272245
Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT00569010
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
Memorial Sloan Kettering Cancer Center
NCT00052572
506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Cancer Institute (NCI)
NCT00003545
VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
Vion Pharmaceuticals
NCT00304005
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Case Comprehensive Cancer Center
NCT00054327
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center
NCT00109993
Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia
Mayo Clinic
NCT00562328
Erwinase Study in Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT00506597
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
NCT00589563
Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
M.D. Anderson Cancer Center
NCT01752426
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia
University of Nebraska
NCT00002638
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Fred Hutchinson Cancer Center
NCT00002674
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT01094860
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
NCT00104923
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
Pediatric Brain Tumor Consortium
NCT00006246
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
Roswell Park Cancer Institute
NCT00003294
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
H. Lee Moffitt Cancer Center and Research Institute
NCT00387647
Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Ohio State University Comprehensive Cancer Center
NCT00624936
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
NCT01168921
ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
National Institutes of Health Clinical Center (CC)
NCT00387608
Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)
H. Lee Moffitt Cancer Center and Research Institute
NCT00840931
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT00620633
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
NCT00274846
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
H. Lee Moffitt Cancer Center and Research Institute
NCT02403310
Circulating microRNAs as Disease Markers in Pediatric Cancers
Ann & Robert H Lurie Children's Hospital of Chicago
NCT01541800
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Prescient Therapeutics
NCT00642031
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
New York Medical College
NCT01049854
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 98 |
| Phase 2 | 95 |
| Phase 3 | 18 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leukemia page
274 registered trials, 51 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 51 Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukemia condition card totals 274 registered trials; most-linked intervention cyclophosphamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.